` FULC (Fulcrum Therapeutics Inc) vs S&P 500 Comparison - Alpha Spread

FULC
vs
S&P 500

Over the past 12 months, FULC has underperformed S&P 500, delivering a return of -11% compared to the S&P 500's +13% growth.

Stocks Performance
FULC vs S&P 500

Loading
FULC
S&P 500
Add Stock

Performance Gap
FULC vs S&P 500

Loading
FULC
S&P 500
Difference
www.alphaspread.com

Performance By Year
FULC vs S&P 500

Loading
FULC
S&P 500
Add Stock

Competitors Performance
Fulcrum Therapeutics Inc vs Peers

S&P 500
FULC
LLY
JNJ
NOVO B
ROG
Add Stock

Fulcrum Therapeutics Inc
Glance View

Market Cap
412.9m USD
Industry
Pharmaceuticals

Fulcrum Therapeutics, Inc. is a clinical stage biopharmaceutical company. The company is headquartered in Cambridge, Massachusetts and currently employs 104 full-time employees. The company went IPO on 2019-07-18. The firm focuses on improving the lives of patients with genetically defined rare diseases. The firm has developed a product engine which identifies drug targets which can modulate gene expression to treat the known root cause of gene mis-expression. The firm is also engaged in developing drugs for the treatment for the root cause of muscle disorders, central nervous system disorders and blood disorders. The firm uses its proprietary product engine to identify and validate drug targets and develop product candidates to address diseases caused by the mis-expression of certain genes. Its product candidate includes losmapimod, is a small molecule that is developed for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, is a small molecule designed to bind embryonic ectoderm development (EED).

FULC Intrinsic Value
2.4 USD
Overvaluation 69%
Intrinsic Value
Price
Back to Top